Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis
Elisabeth Jäger,Supriya Murthy,Caroline Schmidt,Magdalena Hahn,Sarah Strobel,Anna Peters,Claudia Stäubert,Pelin Sungur,Tom Venus,Mandy Geisler,Veselina Radusheva,Stefanie Raps,Kathrin Rothe,Roger Scholz,Sebastian Jung,Sylke Wagner,Matthias Pierer,Olga Seifert,Wenhan Chang,Irina Estrela-Lopis,Nora Raulien,Knut Krohn,Norbert Sträter,Stephanie Hoeppener,Torsten Schöneberg,Manuela Rossol,Ulf Wagner
DOI: https://doi.org/10.1038/s41467-020-17749-6
2020-08-25
Abstract:Increased extracellular Ca2+ concentrations ([Ca2+]ex) trigger activation of the NLRP3 inflammasome in monocytes through calcium-sensing receptor (CaSR). To prevent extraosseous calcification in vivo, the serum protein fetuin-A stabilizes calcium and phosphate into 70-100 nm-sized colloidal calciprotein particles (CPPs). Here we show that monocytes engulf CPPs via macropinocytosis, and this process is strictly dependent on CaSR signaling triggered by increases in [Ca2+]ex. Enhanced macropinocytosis of CPPs results in increased lysosomal activity, NLRP3 inflammasome activation, and IL-1β release. Monocytes in the context of rheumatoid arthritis (RA) exhibit increased CPP uptake and IL-1β release in response to CaSR signaling. CaSR expression in these monocytes and local [Ca2+] in afflicted joints are increased, probably contributing to this enhanced response. We propose that CaSR-mediated NLRP3 inflammasome activation contributes to inflammatory arthritis and systemic inflammation not only in RA, but possibly also in other inflammatory conditions. Inhibition of CaSR-mediated CPP uptake might be a therapeutic approach to treating RA.